Surgery Websites
Breast Care Surgery »  Faculty »  Breast Care Surgeons »  Rita Mukhtar, M.D.
Rita Mukhtar, M.D.

Rita Mukhtar, M.D.

  • Associate Professor of Surgery
  • Division of Surgical Oncology
  • Lobular Breast Cancer Research Program

Contact Information

Open Popup

1996-2000 University of California, Berkeley, AB Molecular and Cell Biology

2001-2006 University of California, San Francisco, MD

  • 2006-2012 University of California, San Francisco, Resident, General Surgery
  • 2012-2013 University of California, San Francisco, Chief Resident, General Surgery
  • 2009-2011 University of California, San Francisco, Post-doctoral Research Fellow
  • 2013-2014 University of California, San Francisco, Society of Surgical Oncology Fellow, Breast Surgery
  • 2009-2010 UCSF CTSI Advanced Training in Clinical Research
  • American Board of Surgery, General Surgery
  • Carol Franc Buck Breast Care Center
  • Axillary dissection
  • Breast Surgery
  • Emergency General Surgery
  • Lumpectomy
  • Nipple sparing/total skin sparing mastectomy
  • Seed and wire localization surgery
  • Sentinel lymph node biopsy

Breast oncologic surgeon-scientist Rita Mukhtar, M.D., Associate Professor of Surgery at UCSF, leads clinical and translational research on invasive lobular carcinoma (ILC), the second most common type of breast cancer, and an understudied disease with unique treatment challenges. Funded by the American Cancer Society, the Helen Diller Comprehensive Cancer Center, and the National Cancer Institute, Dr. Mukhtar studies surgical outcomes and treatment response predictors in ILC. Additionally, she is the UCSF Principal Investigator for a surgical window trial testing pre-operative endocrine therapy in ILC. Dr. Mukhtar collaborates with a multidisciplinary team from The Helen Diller Family Comprehensive Cancer Center to advance ILC research and innovate targeted treatment strategies that improve patient lives and outcomes.

Dr Mukhtar completed her undergraduate education at UC Berkeley, where she studied music and molecular biology. She then attended medical school at UCSF, during which time she received a Doris Duke Clinical Research Fellowship and pursued research in the inflammatory response in sepsis, winning a resident research award. She remained at UCSF for General Surgery residency and completed a two year post-doctoral research fellowship focusing on the role of inflammatory cells in breast cancer outcomes, funded by the California Breast Cancer Research Program.

During this time, she received a scholarship from the UCSF Clinical and Translational Science Institute to complete a certificate in Advanced Training in Clinical Research. After residency, she completed a fellowship in breast oncologic surgery. She currently practices breast surgery, including treatment of benign and malignant breast disease, and acute care general surgery.

Data provided by UCSF Profiles, powered by CTSI
Data provided by UCSF Profiles, powered by CTSI
  1. Record H, Clelland E, Rothschild HT, Kaur M, Chien AJ, Melisko M, Rugo HS, Mujir F, Huppert L, Mukhtar RA. Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer. NPJ Breast Cancer. 2023 Oct 26; 9(1):88. View in PubMed
  2. Mukhtar RA, Huppert L, Ramalingam K. Letter to the Editor of Annals of Surgical Oncology concerning "Is Choosing Wisely Wise for Lobular Carcinoma in Patients over 70 Years of Age? A National Cancer Database Analysis of Sentinel Node Practice Patterns". Ann Surg Oncol. 2023 Oct 18. View in PubMed
  3. Parmeshwar N, Dugan CL, Barnes LL, Cheng JK, Patterson AK, Miller A, Mukhtar R, Piper M. ASO Visual Abstract: Nipple-Sparing Mastectomies in Patients over the Age of 60 Years: Factors Associated with Surgical Outcomes. Ann Surg Oncol. 2023 Oct 15. View in PubMed
  4. Rothschild HT, Clelland EN, Abel MK, Chien AJ, Shui AM, Esserman L, Khan SA, Mukhtar RA. The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database (NCDB). Breast Cancer Res Treat. 2023 Oct 13. View in PubMed
  5. Boughey JC, Yu H, Dugan CL, Piltin MA, Postlewait L, Son JD, Edmiston KK, Godellas C, Lee MC, Carr MJ, Tonneson JE, Crown A, Lancaster RB, Woriax HE, Ewing CA, Chau HS, Patterson AK, Wong JM, Alvarado MD, Yang RL, Chan TW, Sheade JB, Ahrendt GM, Larson KE, Switalla K, Tuttle TM, Tchou JC, Rao R, Tamirisa N, Singh P, Gould RE, Terando A, Sauder C, Hewitt K, Chiba A, Esserman LJ, Mukhtar R. ASO Visual Abstract: Changes in Surgical Management of the Axilla Over 11 Years-Report on Over 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial. Ann Surg Oncol. 2023 10; 30(11):6411-6412. View in PubMed
  6. View All Publications


Site Directory